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Abstract  
Summary This study evaluates serum creatine kinase isoen- zyme activity in children with 
osteogenesis imperfecta to de- termine its usefulness as a biochemical marker during treat- 
ment with bisphosphonate. The changes of creatine kinase (CK) isoenzyme activity during and 
after discontinuation ther- apy were observed. These results could be useful in address- ing 
over-treatment risk prevention.  
Introduction The brain isoenzyme of creatine kinase (CKbb) is highly expressed in mature 
osteoclasts during osteoclasto- genesis, thus plays an important role in bone resorption. We 
previously identified high serum CKbb levels in 18 children with osteogenesis imperfect (OI) 
type 1 treated for 1 year with bisphosphonate (neridronate). In the present study, serum CK 
isoenzymes were evaluated in the same children with contin- uous versus discontinued 
neridronate treatment over a further 2-year follow-up period.  
Methods This study included 18 children with OI type 1, 12 with continued (group A) and 6 
with ceased (group B) neridronate treatment. Auxological data, serum biochemical markers of 
bone metabolism, bone mineral density z-score, and serum total CK and isoenzyme activities 
were determined in both groups.  
Results Serum CKbb was progressively and significantly in- creased in group A (p < 0.004) but 
rapidly decreased to unde- tectable levels in group B. In both groups, the cardiac muscle  
creatine kinase isoenzyme (CKmb) showed a marked de- crease, while serum C-terminal 
telopeptide (CTx) levels were almost unchanged. Conclusions This study provides evidence of 
the cumulative effect of neridronate administration in increasing serum CKbb levels and the 
reversible effect after its discontinuation. This approach could be employed for verifying the 
usefulness of serum CKbb as a biochemical marker in patients receiving prolonged 
bisphosphonate treatment. Moreover, the decreased serum CKmb levels suggest a systemic 
effect of these drugs.  
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Introduction  
Creatine kinase (CK) is a dimeric enzyme that catalyzes the reversible reaction of creatine and 
adenosine triphosphate (ATP) to form phosphocreatine and adenosine diphosphate (ADP), a 
crucial reaction for cellular energy generation and metabolism [1]. The three known cytosolic 
CK isoenzymes include brain (CKbb), sarcomeric muscle (CKmm), and car- diac muscle 
(CKmb) types [2]. CKbb is present in a range of tissues including the brain, retina, uterus, 
testes, and bone, in which it executes the function of energy maintenance and regulation [1].  
It has been reported that the CKbb gene is highly expressed in rabbit osteoclasts [3] and that 
receptor activator of nuclear factor kappa-B ligand (RANKL) up-regulates CKbb during 
osteoclastogenesis [4]. Moreover, the decrease of CKbb ex- pression by RNA interference 
suppresses bone resorption by osteoclasts grown in vitro, showing that CKbb has a crucial role 
in bone remodeling [5].  
In humans, elevation of serum levels of CKbb has been found in some types of osteopetrosis 
(OPT), a genetic disease in which osteoclasts fail to resorb bone; therefore, CKbb is proposed 
as a biochemical marker to distinguish true OPT from other sclerosing bone disorders [6–10]. 
Interestingly, se- rum CKbb has been reported to increase in patients affected by OPT as a 
consequence of bisphosphonate (BP) therapy [11, 12].  
Osteogenesis imperfecta (OI) is a heritable, heterogeneous connective tissue disorder, causing 
bone fragility and several other connective tissue abnormalities with severities ranging from 
asymptomatic individuals to perinatal death. Osteoblasts in OI patients are unresponsive to 
mechanical load; therefore, they produce an abnormal bone matrix. To compensate for this, the 
osteoblast population increases alongside increased osteoclast activity, leading to a high bone 
turnover rate [13]. Other than bone fragility, OI is characterized by low bone mineral density 
(BMD), increased fracture rate, short stature, skeletal deformities, blue sclerae, dentinogenesis 
imperfecta, joint laxity, and deafness later in life [14]. On the basis of clinical, radiological, and 
genetic features, several OI types have been described [15], with type 1 being the mildest [16].  
BPs are considered the treatment of choice in children with OI [17, 18]. These synthetic 
analogs of inorganic pyrophosphate strongly inhibit bone resorption by sup- pressing the 
activity of osteoclasts and shortening their life span [19].  
In 2004, we reported an increased serum CKbb level in 18 children with OI type 1 during the 
first year of treatment with neridronate [20]. Recently, BP treatment was reported to result in 
increased CK release from rabbit osteoclasts in vitro [21]. This result explains a possible 
mechanism for increased serum CK in patients treated with BPs [11, 20].  
In the present study, we evaluated serum CK isoenzymes in the same 18 children used in our 
previous study during a further 2-year follow-up period [20]. The study included two groups: 
subjects who continued with neridronate treatment and subjects who discontinued neridronate 
treatment. The aim of this study therefore was to evaluate the effect of BP treatment on serum 
CK isoenzyme activity to determine its usefulness as a biochemical marker during the 
treatment of OI patients.  
Subjects and methods  
Written informed consent was obtained from all patient par- ents prior to patient inclusion in 
the study. The study protocol was approved by the ethics committee of the Department of 
Pediatrics, Sapienza University of Rome.  
This study included 18 children affected by OI type 1 who received 1 year neridronate 
treatment as described in our previous report [20]. Twelve children, five boys, and  
seven girls (mean age [years] ± standard deviation [SD]: 6.7 ± 1.5) continued neridronate 
treatment throughout the 2-year follow-up period (group A). Six children, four boys, and two 
girls (mean age [years] ± SD: 5.2 ± 3) discontinued neridronate treatment (group B) after 
reaching lumbar spine BMD (z-score) values of ±0.1, in accordance with our protocol 
treatment of OI. All children were followed up for 2 years as outpatients in the Department of 
Pediatrics, Sapienza University of Rome. Exclusion criteria were the occurrence of fractures 
during the study, assumption of drugs, and/or acute illness inter- fering in bone metabolism. 
Neridronate (sodium neridronate, ABIOGEN PHARMA SpA, Pisa, Italy) was administered as 
a single infusion once every 3 months. Each infusion consisted of 2-mg/kg body weight, 
diluted in 100-mL isotonic saline.  
Baseline clinical and biochemical data of group A and group B are reported in Tables 1 and 2, 
respectively. Auxological data and serum biochemical markers of bone metabolism, including 
calcium, phosphate, intact parathy- roid hormone (iPTH), 25 (OH) vitamin D (25(OH)D), basal 
alkaline phosphatase (ALP), C-terminal telopeptide (CTx), lumbar spine radiographs, and 
BMD z-score, were determined in both groups at baseline and at 1 year in the previous study 
[20] and at 2 and 3 years during the follow-up period of the current study. Total serum CK and 
isoenzymes were analyzed in the same samples.  
Serum biochemical studies  
Total serum CK activity was measured in fasting blood sam- ples using the kinetic UV method 
(Instrumentation Laboratory SpA, Milano, Italy) optimized according to the Federation of 
Clinical Chemistry [22]. CK isoenzymes (mm, mb, and bb) were separated by electrophoresis 
on agarose gels. After elec- trophoresis, the sample strips were incubated for 1 h at 37 °C with 
the reaction mixture. Catalytic activity was determined by spectrophotometric measurements as 
described previously [23].  
Isoenzyme activity was expressed as international units per liter (U/L) (Helena Biosciences 
Europe, Sunderland, UK). Serum calcium, phosphate, ALP, iPTH, CTx, and 25(OH)D levels 
were measured using chemiluminescence and an auto- matic analyzer (Roche diagnostic SpS, 
Monza, Italy).  
Radiological studies  
BMD z-score was measured in the lumbar spine (L1–L4) by dual-energy x-ray absorptiometry 
using a Hologic QDR 4500° system with reference values provided by the manufac- turer 
(Hologic, Bedford, MA) [24].  
Statistics  
Statistical differences in demographic, densitometric, and bio- chemical parameters were 
determined within groups. Comparisons between two time points in the same groups were 
carried out using the paired t test. Because the data were approximately log-normally 
distributed, they were log- transformed before statistical analysis. Comparisons between more 
than two time points were performed using analysis of variance (ANOVA) for repeated 
measures. Results were expressed as means ± SD. Significant deviations from the null 
hypothesis were stated when p < 0.05.  
Results  
Total serum CK and isoenzyme levels are reported in Tables 3 and 4 for continued (group A) 
and discontinued (group B) neridronate treatment, respectively. The data include the first year 
of treatment (0 to 1 year) published in our previous study [20] and 2-year observation time of 
the present study (1 to  
3 years). Baseline data were determined before the first cycle of treatment and represent the 
pre-treatment values.  
In group A, serum CKbb showed a progressive increase during the 2-year follow-up that 
became statistically signifi- cant at the end of follow-up (3 vs 1 year; p < 0.004) with a mean 
increase rate of 4.4 U/L/yr. This change was less evident compared with the rapid increase 
observed in the previous study during the first year of neridronate treatment (8.33 U/ L/yr) (Fig. 
1).  
In Group B, serum CKbb exhibited a mild increase in all patients in the first year after 
discontinuing neridronate treatment, followed by a rapid decrease to undetectable levels at the 
end of the 2-year follow-up (3 vs 1 year; p < 0.001). Furthermore, the values were lower than 
those observed at baseline (3 vs 0 year; p < 0.001).  
Regarding serum CKmb, group A showed a slight in- crease after 1 year of observation time 
followed by a marked decrease (3 vs 2 years; p < 0.005) and values were significantly lower 
compared with baseline (3 vs 0 year; p < 0.002) (Table 3, Fig. 1). In group B, serum CKmb 
tended to decrease from 1 year after discontinua- tion of neridronate treatment and was reduced 
to  
undetectable level after the second year (3 vs 1 year; p < 0.002) (Table 4, Fig. 1). In both 
groups, no significant changes were observed in the levels of CKmm isoenzyme (Tables 3 and 
4).  
Total serum CK showed a significant increase after 3 years of treatment compared with pre-
treatment but only in group A (3 vs 0 year; p < 0.05). In both groups, no significant changes in 
total serum CK level were observed during follow-up in the present study.  
Demographic, biochemical, and densitometric characteris- tics of group A and group B are 
reported in Tables 1 and 2, respectively. In group A, BMD z-score increased progressive- ly, 
while in group B there was a slight increase 1 year after discontinuing neridronate treatment, 
with a decrease at the end of follow-up.  
CTx values in both groups remained almost unchanged during the 2-year follow-up time in the 
present study, with lower values in comparison with pre-treatment, which were comparable 
with normal range (Tables 1 and 2; Fig. 2). In both groups, lumbar spine radiographs showed 
no sign of osteosclerosis at the end of the evaluation period.  
Discussion  
In our previous study, we identified a significant increase in serum CKbb after 1 year of 
neridronate treatment in children affected by OI [20]. Because osteoclasts are considered a ma- 
jor target of the pharmacologic action of BPs, and are rich of cytosolic soluble CKbb, we 
postulated that this finding could reflect an osteoclast dysfunction inducing CKbb release. 
Recently, an in vitro study using BP-stimulated rabbit osteo- clasts supported that osteoclasts 
are the main source of CK release from the bone, and that this phenomenon is an osteo- clast 
apoptosis-related event [21]. These observations support the hypothesis that BP-induced 
osteoclast damage could ac- count for serum Ckbb increase in our OI-treated patients, sus- 
taining the role of serum Ckbb as a marker of osteoclast dys- function [6–12].  
In the present study, a significant serum CKbb increase was observed in the 12 children 
receiving continuous neridronate therapy after the 2-year follow-up (group A; 3 vs 0 year). 
However, the rate of this increase (1.5 U/L/year) was lower than that observed during the first 
year of treatment (8.33 U/L/ year). In vitro, CK release from osteoclasts exposed to BPs has 
been shown to be dose-dependent [21]. We therefore ex- pected a linear increase in serum 
CKbb over the study time due to the pharmacological effect of neridronate accumulation in the 
bone matrix. However, the aforementioned in vitro study also demonstrated that reduction of 
the osteoclast pop- ulation occurs when CK release is increased 2.6 times the basal value. 
Therefore, the reduced rate of serum CKbb in- crease observed in the present study could 
reflect reduction of the osteoclast population.  
In group B, the level of serum Ckbb showed a mild in- crease after the first year of 
discontinued neridronate treat- ment, presumably reflecting the action of neridronate accumu- 
lation in the bone matrix during treatment. The rapid decrease to undetectable levels observed 
at the end of follow-up was surprising. In fact, compared with controls, untreated OI pa- tients 
showed slightly elevated serum CKbb levels, likely re- lated to increased bone turnover [20]. 
Therefore, the undetect- able CKbb levels observed 2 years after treatment discontin- uation 
seem to reflect the full suppression of osteoclast  
apoptosis below pre-treatment level. This finding could repre- sent a mechanism finalized to a 
rapid recovery of the osteo- clast population.  
Regarding serum CTx, which reflects osteolytic activity by osteoclasts, we observed 
persistently lower levels in both groups in comparison with pre-treatment. To further evaluate 
these results, we compared them to the serum CKbb levels. In group A, the CTx values 
indicated that residual resorption activity was maintained after prolonged neridronate osteoclast 
exposure, even when a high apoptotic rate occurred, as indi- cated by elevated serum CKbb 
levels. Conversely, in group B, the CTx levels showed that neridronate continued to inhibit 
bone resorption 2 years after discontinuing treatment. This finding is in contrast with the 
undetectable serum CKbb levels observed at this time that reflect the recovery of the anti- 
resorptive activity of osteoclasts. However, the aforemen- tioned in vitro study shows that CK 
release begins to increase following BP exposure resulting in 60 % inhibition of CTx release 
[21]. Therefore, low-level BP exposure may occur, resulting in anti-resorptive activity not 
mediated by osteoclast  
apoptosis. A similar situation could occur in vivo after discon- tinuation of treatment as a 
consequence of the continuous release of BPs accumulated in the bone matrix. This hypoth- 
esis is reasonable considering the two independent signaling pathways by which BPs exert their 
anti-resorptive and pro- apoptotic effects on osteoclasts [25, 26].  
Taken together, these data show that neridronate exerts a high and constant inhibitory effect on 
osteoclast activity over a wide exposure-time range. Maximum anti-resorptive activity is 
obtained after the first year of treatment when CKbb release is augmented threefold. 
Furthermore, basal resorption activity is not abolished after long-term exposure when serum 
CKbb is strongly augmented. Moreover, neridronate continues to exert its maximal inhibition 
on bone resorption up to 2 years after discontinuation of treatment when serum CKbb is 
undetect- able. It is likely that serum CKbb has a different indication in relation to therapy. For 
example, in patients who have under- gone 1 year of treatment, a threefold increase seems to 
indicate the maximum inhibition of osteolytic activity, whereas in pa- tients who discontinued 
treatment, reduction of serum CKbb  
L/year) and lower increase in the further 2-year treatment (4.4 U/L/year) without evidence of plateau. Vertical 
bars represent SD. NER start start of neridronate treatment, NER stop stop of neridronate treatment. The shadow 
area shows the range of serum CKbb and CKmb values obtained from 20 healthy children matched for sex and 
age [20]  
does not predict the recovery to pre-treatment levels of osteolytic activity. These concepts are 
only an inference of our results in the light of evidence emerging following in vitro studies. 
Further studies are needed to elucidate if they are useful for clinical purpose.  
Another interesting finding from our study regards serum CKmb, the specific cytosolic cardiac 
isoform [2]. It is well known that BPs exert their specific action on bone resorption because 
they accumulate by affinity in the bone matrix and are solubilized prior to ingestion by 
osteoclasts during osteolytic activity [25, 26]. In the previous report, we found that the pre- 
treatment serum CKmb level was significantly higher com- pared with the control, although 
cardiovascular disease was excluded in the study population [20]. In the present study, we 
observed an intriguing reduction in serum CKmb in both groups during the second year of 
follow-up. These results suggest a possible systemic effect of BPs that implicates a different 
mechanism of entry through the plasma membrane in non-bone tissue cells. Moreover, it seems 
that neridronate, even after discontinuation, continues to exert an effect on  
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Fig. 2 Changes of serum CTX in 12 children who continued neridronate treatment (group A) and in 6 children 
who stopped neridronate treatment after 1 year (group B). The data include the first year of treatment (0 to 1 
year) published in our previous study [20] and 2-year observation time  
CKmb release by cardiomyocytes. Further studies are needed to elucidate if this observation is 
merely an epiphenomenon or could correlate with clinical cardiological parameters in these 
patients.  
Our study has a number of limitations. First, the rela- tively small sample size limited the 
power of our statisti- cal analysis, restricting statistically significant correlations to be obtained 
with clinical parameters. Studies in larger cohorts (multicentric studies) are therefore required 
to bet- ter elucidate the usefulness of our results for clinical pur- pose. Second, we interpreted 
our in vivo results using evidence from an animal in vitro study that demonstrated the release 
of CK from cultured osteoclasts via the phar- macological action of BPs. Third, in the OI 
children who continued neridronate therapy, we observed a progressive increase of serum 
CKbb level without evidence of a pla- teau. In children who discontinued therapy, we did not 
observe recovery to pre-treatment levels at the end of the follow-up time. Therefore, further 
follow-up will be necessary to completely evaluate the variations of serum CKbb in relation to 
therapy.  
In conclusion, this study provides evidence of the cu- mulative effect of neridronate 
administration in increasing serum CKbb levels and the reversible effect after its dis- 
continuation. These data could be employed in verifying the usefulness of serum CKbb as a 
biochemical marker for clinical purpose in patients receiving prolonged BP treatment, 
especially regarding the prevention of over- treatment risk. This knowledge will be of 
particular inter- est considering the lack of consensus on criteria to initiate treatment, determine 
treatment duration, and evaluate  
of the present study (1 to 3 years). Vertical bars represent SD. NER start start of neridronate treatment, NER stop 
stop of neridronate treatment. The shadow area shows the range of serum CTX normal values  
long-term safety, especially in the pediatric population. Moreover, the decrease of serum 
CKmb suggests a sys- temic effect of these drugs, whose implications are not yet known, and 
needs to be investigated in future studies.  
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